Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + LDAC Expanded Access in Japanese AML
NCT04509622Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Oct 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04509622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509622.